A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Summary

This is a phase III clinical trial to evaluate the efficacy and safety of XZP-3287 in combination with Fulvestrant versus placebo combined with Fulvestrant in Patients who have HR positive and Her2 negative recurrent/metastatic breast cancer and have received prior endocrine therapy are eligible for study.

Timeline

Start

2021-11-16

Primary completion

2024-02-22

Completion

2029-11

Publications

• Wang J, Zhang Q, Li H, Tong Z, Ouyang Q, Li H, Teng Y, Wang B, Sun T, Wang J, Li W, Niu Z, Li H, Gong C, Wang S, Wang X, Wu X, Liu N, Yu G, Hu Y, Wang Q, Duan X, Yang F, Wang L, Xu B. Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2026 May 1;12(5):488-496. doi: 10.1001/jamaoncol.2026.0318.

Drugs

Indications